NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
6/8 — Strong
BARHEMSYS (amisulpride) by Acacia Pharma is dopamine d2 antagonists [moa]. Approved for schizophrenia, postoperative nausea and vomiting. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BARHEMSYS (amisulpride) is an intravenous dopamine D2 receptor antagonist approved in 2020 for schizophrenia and postoperative nausea and vomiting (PONV). It works by blocking dopamine signaling in the central nervous system to reduce psychotic symptoms and nausea. The IV route provides rapid onset, making it particularly valuable in acute care settings.
Peak11.8 years to LOE
At peak lifecycle with strong patent protection through 2038, BARHEMSYS is in active commercialization phase; career opportunities exist in sales, medical affairs, and brand management roles.
Mechanism of Action
Dopamine D2 Antagonists
Pharmacologic Class:
Dopamine-2 Receptor Antagonist
Indications (2)
Worked on BARHEMSYS at Acacia Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.